ABSTRACT
AIM: To evaluate the effect of the I(f) channel blocker ivabradine on bronchial patency and the volume parameters of external respiration function in patients with chronic obstructive pulmonary disease (COPD) in remission in order to determine whether the drug may be used in patients with coronary heart disease (CHD) concurrent with COPD. SUBJECTS AND METHODS: Heart rate, bronchial patency, and lung volume were studied by body plethysmography in 59 patients with COPD before and 14 days after administration of ivabradine in a daily dose of 10 mg. RESULTS: The I(f) channel blocker ivabradine that is a highly selective bradycardiac agent fails to affect the velocity and volume parameters of external respiration function, thus it may be used to treat CHD concurrent with COPD. CONCLUSION: The I(f) channel blocker ivabradine exerts no effect on external respiration function parameters (bronchial patency, volume parameters) and it can find clinical use in the treatment of angina pectoris and chronic heart failure in patients with CHD concurrent with COPD.
Subject(s)
Benzazepines/therapeutic use , Cardiovascular Agents/therapeutic use , Cyclic Nucleotide-Gated Cation Channels/antagonists & inhibitors , Heart Rate/drug effects , Pulmonary Disease, Chronic Obstructive/complications , Respiration/drug effects , Aged , Benzazepines/administration & dosage , Benzazepines/adverse effects , Cardiovascular Agents/administration & dosage , Cardiovascular Agents/adverse effects , Electrocardiography , Female , Humans , Ivabradine , Male , Middle Aged , Myocardial Ischemia/complications , Myocardial Ischemia/drug therapy , Myocardial Ischemia/metabolism , Pulmonary Disease, Chronic Obstructive/drug therapy , Pulmonary Disease, Chronic Obstructive/metabolism , Pulmonary Disease, Chronic Obstructive/physiopathology , Respiratory Function TestsABSTRACT
AIM: To evaluate influence of the treatment with systemic glucocorticoid hormones (SGH) during acute exacerbation of moderate and severe chronic obstructive pulmonary disease (COPD) on parameters of respiratory function. MATERIAL AND METHODS: A total of 66 patients with severe COPD were included in the study. Airway resistance and lung volumes were measured with plethysmography, lung diffusion capacity - with a single breath method (TLCO SB) and saturation of blood with oxygen was measured with a method of pulseoximetry at admission of patients to a hospital and on day 14 of SGH treatment. RESULTS: Improvement of FEV1 by 26.3%, and a decrease in airway resistance by 44.2% (group 1) were observed only in 20 of 66 patients. In 46 patients improvement of airflow obstruction has not taken place (group 2). Dynamics of lung diffusion capacity and oxygen blood saturation were positive in both investigated groups of patients. TLCO SB has increased by 47.6% in group 1 and by 15.5% in group 2. O2 saturation has increased by 3.2 and 3.1%, respectively. CONCLUSION: COPD symptoms attenuation in patients treated with SCH was associated with an increase in lung diffusion capacity and blood oxygen. Parameters of standard spirometry (FEV1 and FEV1/FVC do not reflect positive results of therapy.
